Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. Senan S, et al. Among authors: iscoe n. J Clin Oncol. 2016 Mar 20;34(9):953-62. doi: 10.1200/JCO.2015.64.8824. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811519 Clinical Trial.
An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer.
Wang L, Wu YL, Lu S, Deng L, Ahn MJ, Hsu FM, Iscoe N, Hossain A, Puri T, Zhang P, Orlando M. Wang L, et al. Among authors: iscoe n. Asia Pac J Clin Oncol. 2016 Dec;12(4):380-387. doi: 10.1111/ajco.12513. Epub 2016 Jun 17. Asia Pac J Clin Oncol. 2016. PMID: 27312514 Clinical Trial.
PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology.
Vokes EE, Senan S, Treat JA, Iscoe NA. Vokes EE, et al. Clin Lung Cancer. 2009 May;10(3):193-8. doi: 10.3816/CLC.2009.n.027. Clin Lung Cancer. 2009. PMID: 19443340 Clinical Trial.
Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial.
Brade AM, Wenz F, Koppe F, Lievens Y, San Antonio B, Iscoe NA, Hossain A, Chouaki N, Senan S. Brade AM, et al. Among authors: iscoe na. Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):927-934. doi: 10.1016/j.ijrobp.2018.04.015. Epub 2018 Apr 12. Int J Radiat Oncol Biol Phys. 2018. PMID: 29976505 Clinical Trial.
Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer.
Brade A, MacRae R, Laurie SA, Bezjak A, Burkes R, Chu Q, Goffin JR, Cho J, Hope A, Sun A, Leighl N, Capobianco S, Feld R, Mahalingam E, Hossain A, Iscoe N, Shepherd FA. Brade A, et al. Among authors: iscoe n. Clin Lung Cancer. 2016 Mar;17(2):133-41. doi: 10.1016/j.cllc.2015.12.008. Epub 2015 Dec 21. Clin Lung Cancer. 2016. PMID: 26872764 Clinical Trial.
Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer.
Brade A, Bezjak A, MacRae R, Laurie S, Sun A, Cho J, Leighl N, Pearson S, Southwood B, Wang L, McGill S, Iscoe N, Shepherd FA. Brade A, et al. Among authors: iscoe n. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1395-401. doi: 10.1016/j.ijrobp.2010.01.014. Epub 2010 Jun 3. Int J Radiat Oncol Biol Phys. 2011. PMID: 20605367 Clinical Trial.
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.
Chiappori A, Bepler G, Barlesi F, Soria JC, Reck M, Bearz A, Barata F, Scagliotti G, Park K, Wagle A, Liepa AM, Zhao YD, Chouaki N, Iscoe N, von Pawel J. Chiappori A, et al. Among authors: iscoe n. J Thorac Oncol. 2010 Mar;5(3):369-75. doi: 10.1097/JTO.0b013e3181cee24f. J Thorac Oncol. 2010. PMID: 20090562 Free article. Clinical Trial.
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K. Rusthoven JJ, et al. Among authors: iscoe na. J Clin Oncol. 1996 Jul;14(7):2083-90. doi: 10.1200/JCO.1996.14.7.2083. J Clin Oncol. 1996. PMID: 8683240 Clinical Trial.
A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.
Cullen MH, Zatloukal P, Sörenson S, Novello S, Fischer JR, Joy AA, Zereu M, Peterson P, Visseren-Grul CM, Iscoe N. Cullen MH, et al. Among authors: iscoe n. Ann Oncol. 2008 May;19(5):939-45. doi: 10.1093/annonc/mdm592. Epub 2008 Feb 17. Ann Oncol. 2008. PMID: 18283036 Free article. Clinical Trial.
49 results